Abstract:Introduction: The clinical use of the antitumoral drug doxorubicin (Dox) is reduced by its dose-limiting toxicity, related to cardiotoxic side effects and myelosuppression. In order to overcome these drawbacks, here we describe the synthesis, the structural characterization and the in vitro cytotoxicity assays of hydrogels (HGs) and nanogels (NGs) based on short peptide sequences loaded with Dox or with its liposomal formulation, Doxil. Methods: Fmoc-FF alone or in combination with (FY)3 or PEG8-(FY)3 peptides, at two different ratios (1/1 and 2/1 v/v), were used for HGs and NGs formulations. HGs were prepared according to the "solvent-switch" method, whereas NGs were obtained through HG submicronition by the top-down methodology in presence of TWEEN®60 and SPAN®60 as stabilizing agents. HGs gelation kinetics were assessed by Circular Dichroism (CD). Stability and size of NGs were studied using Dynamic Light Scattering (DLS) measurements. Cell viability of empty and filled Dox HGs and NGs was evaluated on MDA-MB-231 breast cancer cells. Moreover, cell internalization of the drug was evaluated using immunofluorescence assays. Results: Dox filled hydrogels exhibit a high drug loading content (DLC=0.440), without syneresis after 10 days. Gelation kinetics (20-40 min) and the drug release (16-28%) over time of HGs were found dependent on relative peptide composition. Dox filled NGs exhibit a DLC of 0.137 and a low drug release (20-40%) after 72 h. Empty HGs and NGs show a high cell viability (>95%), whereas Dox loaded ones significantly reduce cell viability after 24 h (49-57%) and 72 h (7-25%) of incubation, respectively. Immunofluorescence assays evidenced a different cell localization for Dox delivered through HGs and NGs with respect to the free drug. Discussion: A modulation of the Dox release can be obtained by changing the ratios of the peptide components. The different cellular localization of the drug loaded into HGs and NGs suggests an alternative internalization mechanism. The high DLC, the low drug release and preliminary in vitro results suggest a potential employment of peptide-based HGs and NGs as drug delivery tools.

Injectable Doxorubicin-Loaded Hydrogels Based on Dendron-Like Β-Cyclodextrin–poly(ethylene Glycol) Conjugates

Peptide-Based Hydrogels and Nanogels for Delivery of Doxorubicin

An Injectable Drug-Loaded Hydrogel Based on a Supramolecular Polymeric Prodrug.

Injectable poly(ethylene glycol) hydrogels for sustained doxorubicin release

Poly(ethyleneglycol)-b-poly(ε-caprolactone-co-γ-hydroxyl-ε- Caprolactone) Bearing Pendant Hydroxyl Groups As Nanocarriers for Doxorubicin Delivery.

Biocompatible supramolecular hydrogels based on polysaccharide-modified hyaluronic acid for targeted delivering of doxorubicin

Ionic Microgel Loaded with Gold Nanoparticles for the Synergistic Dual-Drug Delivery of Doxorubicin and Diclofenac Sodium

A hyperbranched amphiphilic acetal polymer for pH-sensitive drug delivery

Ph Triggered Injectable Amphiphilic Hydrogel Containing Doxorubicin and Paclitaxel

An injectable and biodegradable hydrogel based on poly(α,β-aspartic acid) derivatives for localized drug delivery

Biodegradable Strain-Promoted Click Hydrogels for Encapsulation of Drug-Loaded Nanoparticles and Sustained Release of Therapeutics

Injectable small molecule hydrogel as a potential nanocarrier for localized and sustained in vivo delivery of doxorubicin

In situ Hydrogels Prepared by Photo-initiated Crosslinking of Acrylated Polymers for Local Delivery of Antitumor Drugs

Dual‐Crosslinked Human Serum Albumin‐Polymer Hydrogels for Affinity‐Based Drug Delivery

Injectable hyaluronic acid–cyclodextrin-based hydrogels for localized and sustained release of anticancer drugs

Self-Assembly Assisted Fabrication of Dextran-Based Nanohydrogels with Reduction-Cleavable Junctions for Applications as Efficient Drug Delivery Systems

Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy

Zwitterionic Supramolecular Prodrug Nanoparticles Based on Host-Guest Interactions for Intracellular Drug Delivery

Shear-responsive Injectable Supramolecular Hydrogel Releasing Doxorubicin Loaded Micelles with Ph-Sensitivity for Local Tumor Chemotherapy.

An acid-labile bridged β-CD-based nano-hydrogel with superior anti-tumor drug delivery and release capacity

Injectable Thermosensitive Polypeptide-Based CDDP-Complexed Hydrogel for Improving Localized Antitumor Efficacy.